Tradestie Institutional Equity Comparison Engine
XBIO vs EYEG โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XBIO Overall Edge
XBIO Captures Institutional Edge (1โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xenetic Biosciences, Inc. (XBIO) driven by superior Growth & Margin while EYEG counters with relative strength in Momentum & Technical. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus EYEG at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against EYEG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
XBIO N/M vs EYEG N/M Fwd P/E
Growth & Margin Winner
XBIO
Op Margin -81.0% vs N/A ยท YoY +12.0% vs N/A
Momentum & Technical Winner
EYEG
1Y -44.9% vs -6.4% ยท 52W Pos 4% vs 15%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XBIO
NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.40
-9.09% 1D
Market Cap
$3.6M
1M Return
-27.46%
1Y Return
-44.88%
Forward P/E
N/M
Unified AI Score
43.5 / 100
HOLD
Tech 25.0
Fund 56.0
Flow 50.0
Mom 55.0
EYEG
US Equity
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap
N/A
1M Return
+0.42%
1Y Return
-6.36%
Forward P/E
N/M
Unified AI Score
55.0 / 100
HOLD
Tech 73.0
Fund 61.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XBIO -44.88%
EYEG -6.36%
Spread: +39.01 pp (EYEG Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
XBIO TTM Op. Margin: -81.0%
EYEG TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs EYEG. Trailing 12-month operating profitability (XBIO -81.0% vs EYEG N/A) and valuation multiples (XBIO N/M vs EYEG N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XBIO | EYEG | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6M | N/A | Larger Scale | XBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +12.0% | N/A | Higher Growth | XBIO |
| Operating Margin (TTM) Profitability | -81.0% | N/A | Higher Margin | XBIO |
| Net Profit Margin Profitability | -75.9% | N/A | Higher Margin | XBIO |
| Return on Equity (ROE) Capital Efficiency | -47.0% | N/A | Higher ROE | XBIO |
| 52-Week Range Position Momentum | 4% ($1โ$5) | 15% ($33โ$36) | Stronger Trend | EYEG |
| Beta / 30D Volatility Risk Regime | 1.40ฮฒ ยท 99% Vol | 0.13ฮฒ ยท 5% Vol | Lower Realized Risk | EYEG |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 55.0 / 100 (HOLD) | Higher Composite | EYEG |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XBIO vs EYEG Buy Guide
XBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
EYEG
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XBIO nor EYEG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.